Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Genetically Engineered T Regs for Use in Suppression of Autoimmune and Inflammatory Diseases
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID:
A novel, lymphocyte-based treatment for autoimmune and inflammatory diseases.Inflammation-based disorders include a wide range of diseases such as autoimmune diseases, graft rejection, graft versus host syndromes and inflammation induced malignancies.......
Contact Galit Mazooz, ph.d.
Participants
You
Email me a copy of this message

A novel, lymphocyte-based treatment for autoimmune and inflammatory diseases.
Inflammation-based disorders include a wide range of diseases such as autoimmune diseases, graft rejection, graft versus host syndromes and inflammation induced malignancies. Despite formidable efforts to develop newer and better agents for treating these conditions, frustratingly few novel drugs have passed muster in clinical trials and reached the market in the last decade. The current treatments for such diseases are symptomatic, non-specific and of a short range. The market continues to eagerly await safe and effective alternatives to existing therapies. Consequently, there is a significant unmet need for a disease-specific and durable therapy. The present technology offers a method to genetically manipulate Regulatory T cells (Tregs) such that their suppressive effect on acute inflammation states is greatly enhanced.


Applications








    • Treatment of autoimmune diseases such as colitis, multiple sclerosis, rheumatoid arthritis, diabetes type I, etc.








    • Treatment of inflammatory diseases.








    • Suppression of graft rejection.








    • Suppression of Graft versus Host disease.






Advantages








    • Antigen specific Tregs offers disease-specific and durable therapy.








    • The method is able to obtain large amounts of functional specific Tregs.








    • Tregs can be targeted to suppress local inflammation caused by a yet unknown pathogen.






Technology's Essence


The level of Tregs in the human body is very low and although some suppressive effect of normal Tregs could be shown in animal models, it is rather impractical to obtain an effective therapeutic dose of such cells for clinical treatments. In contrary, treatment with redirected genetically engineered Tregs show more than 10 fold suppressive, therapeutic effect in mice suffering from acute colitis. The outlined technology which was tested in animal models relies on ex vivo modification of the patient’s own Tregs, using DNA encoding chimeric receptor whose recognition unit is engineered to bind the desired antigen. The resulting cells are selected and propagated in vitro and can be then administered to the patient as well be stored frozen for further treatments.


Licensing Status

GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION